Molecular classification of low-grade diffuse gliomas - PubMed (original) (raw)
. 2010 Dec;177(6):2708-14.
doi: 10.2353/ajpath.2010.100680. Epub 2010 Nov 12.
Sumihito Nobusawa, Michel Mittelbronn, Werner Paulus, Benjamin Brokinkel, Kathy Keyvani, Ulrich Sure, Karsten Wrede, Yoichi Nakazato, Yuko Tanaka, Anne Vital, Luigi Mariani, Robert Stawski, Takuya Watanabe, Umberto De Girolami, Paul Kleihues, Hiroko Ohgaki
Affiliations
- PMID: 21075857
- PMCID: PMC2993282
- DOI: 10.2353/ajpath.2010.100680
Molecular classification of low-grade diffuse gliomas
Young-Ho Kim et al. Am J Pathol. 2010 Dec.
Abstract
The current World Health Organization classification recognizes three histological types of grade II low-grade diffuse glioma (diffuse astrocytoma, oligoastrocytoma, and oligodendroglioma). However, the diagnostic criteria, in particular for oligoastrocytoma, are highly subjective. The aim of our study was to establish genetic profiles for diffuse gliomas and to estimate their predictive impact. In this study, we screened 360 World Health Organization grade II gliomas for mutations in the IDH1, IDH2, and TP53 genes and for 1p/19q loss and correlated these with clinical outcome. Most tumors (86%) were characterized genetically by TP53 mutation plus IDH1/2 mutation (32%), 1p/19q loss plus IDH1/2 mutation (37%), or IDH1/2 mutation only (17%). TP53 mutations only or 1p/19q loss only was rare (2 and 3%, respectively). The median survival of patients with TP53 mutation ± IDH1/2 mutation was significantly shorter than that of patients with 1p/19q loss ± IDH1/2 mutation (51.8 months vs. 58.7 months, respectively; P = 0.0037). Multivariate analysis with adjustment for age and treatment confirmed these results (P = 0.0087) and also revealed that TP53 mutation is a significant prognostic marker for shorter survival (P = 0.0005) and 1p/19q loss for longer survival (P = 0.0002), while IDH1/2 mutations are not prognostic (P = 0.8737). The molecular classification on the basis of IDH1/2 mutation, TP53 mutation, and 1p/19q loss has power similar to histological classification and avoids the ambiguity inherent to the diagnosis of oligoastrocytoma.
Figures
Figure 1
Age distribution of patients with and without IDH1/2 mutations in low-grade diffuse gliomas. Note that low-grade diffuse gliomas without IDH1/2 mutations develop in younger patients (mean, 42.1 versus 35.8 years; P = 0.0017).
Figure 2
Upper panel: The survival of patients with diffuse astrocytoma is significantly shorter than that of patients with oligodendroglioma (left). This difference was also clearly observed when tumors were classified genetically (right). Lower panel: Patients with diffuse astrocytoma and those with low-grade diffuse glioma carrying TP53 mutation + IDH1/2 mutation have very similar survival (left). Patients with oligodendroglioma and those with low-grade diffuse glioma carrying 1p/19q loss + IDH1/2 mutation have very similar survival (right).
Similar articles
- Prognostic Relevance of Histomolecular Classification of Diffuse Adult High-Grade Gliomas with Necrosis.
Figarella-Branger D, Mokhtari K, Colin C, Uro-Coste E, Jouvet A, Dehais C, Carpentier C, Villa C, Maurage CA, Eimer S, Polivka M, Vignaud JM, Laquerriere A, Sevestre H, Lechapt-Zalcman E, Quintin-Roué I, Aubriot-Lorton MH, Diebold MD, Viennet G, Adam C, Loussouarn D, Michalak S, Rigau V, Heitzmann A, Vandenbos F, Forest F, Chiforeanu D, Tortel MC, Labrousse F, Chenard MP, Nguyen AT, Varlet P, Kemeny JL, Levillain PM, Cazals-Hatem D, Richard P, Delattre JY; POLA Network. Figarella-Branger D, et al. Brain Pathol. 2015 Jul;25(4):418-28. doi: 10.1111/bpa.12227. Epub 2014 Dec 31. Brain Pathol. 2015. PMID: 25407774 Free PMC article. - Molecular classification of adult diffuse gliomas: conflicting IDH1/IDH2, ATRX, and 1p/19q results.
Ballester LY, Huse JT, Tang G, Fuller GN. Ballester LY, et al. Hum Pathol. 2017 Nov;69:15-22. doi: 10.1016/j.humpath.2017.05.005. Epub 2017 May 23. Hum Pathol. 2017. PMID: 28549927 - Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.
Weller M, Weber RG, Willscher E, Riehmer V, Hentschel B, Kreuz M, Felsberg J, Beyer U, Löffler-Wirth H, Kaulich K, Steinbach JP, Hartmann C, Gramatzki D, Schramm J, Westphal M, Schackert G, Simon M, Martens T, Boström J, Hagel C, Sabel M, Krex D, Tonn JC, Wick W, Noell S, Schlegel U, Radlwimmer B, Pietsch T, Loeffler M, von Deimling A, Binder H, Reifenberger G. Weller M, et al. Acta Neuropathol. 2015 May;129(5):679-93. doi: 10.1007/s00401-015-1409-0. Epub 2015 Mar 18. Acta Neuropathol. 2015. PMID: 25783747 - Genetic profile of astrocytic and oligodendroglial gliomas.
Ohgaki H, Kleihues P. Ohgaki H, et al. Brain Tumor Pathol. 2011 Jul;28(3):177-83. doi: 10.1007/s10014-011-0029-1. Epub 2011 Mar 26. Brain Tumor Pathol. 2011. PMID: 21442241 Review. - Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors.
Malzkorn B, Reifenberger G. Malzkorn B, et al. Pathologe. 2019 Jun;40(Suppl 1):9-17. doi: 10.1007/s00292-019-0581-8. Pathologe. 2019. PMID: 31025086 Review. English.
Cited by
- Beyond invasive biopsies: using VASARI MRI features to predict grade and molecular parameters in gliomas.
Setyawan NH, Choridah L, Nugroho HA, Malueka RG, Dwianingsih EK. Setyawan NH, et al. Cancer Imaging. 2024 Jan 2;24(1):3. doi: 10.1186/s40644-023-00638-8. Cancer Imaging. 2024. PMID: 38167551 Free PMC article. - Differential metabolic alterations in IDH1 mutant vs. wildtype glioma cells promote epileptogenesis through distinctive mechanisms.
McAfee D, Moyer M, Queen J, Mortazavi A, Boddeti U, Bachani M, Zaghloul K, Ksendzovsky A. McAfee D, et al. Front Cell Neurosci. 2023 Nov 9;17:1288918. doi: 10.3389/fncel.2023.1288918. eCollection 2023. Front Cell Neurosci. 2023. PMID: 38026690 Free PMC article. Review. - A pyroptosis gene-based prognostic model for predicting survival in low-grade glioma.
Wang H, Yan L, Liu L, Lu X, Chen Y, Zhang Q, Chen M, Cai L, Dai Z. Wang H, et al. PeerJ. 2023 Nov 13;11:e16412. doi: 10.7717/peerj.16412. eCollection 2023. PeerJ. 2023. PMID: 38025749 Free PMC article. - TP53 Mutation Is a Prognostic Factor in Lower Grade Glioma and May Influence Chemotherapy Efficacy.
Noor H, Briggs NE, McDonald KL, Holst J, Vittorio O. Noor H, et al. Cancers (Basel). 2021 Oct 26;13(21):5362. doi: 10.3390/cancers13215362. Cancers (Basel). 2021. PMID: 34771529 Free PMC article. - Prediction of Malignant Transformation of WHO II Astrocytoma Using Mathematical Models Incorporating Apparent Diffusion Coefficient and Contrast Enhancement.
Wong AM, Siow TY, Wei KC, Chen PY, Toh CH, Castillo M. Wong AM, et al. Front Oncol. 2021 Sep 29;11:744827. doi: 10.3389/fonc.2021.744827. eCollection 2021. Front Oncol. 2021. PMID: 34660309 Free PMC article.
References
- Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol. 2005;64:479–489. - PubMed
- Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008;116:597–602. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous